ATRC Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -12.53% compared to AtriCure's net margin of -18.58%. AtriCure's return on equity of -9.67% beat Retractable Technologies's return on equity of -16.83%.

AtriCure has a consensus price target of $52.22, signalling upside risk potential of 64.07%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that AtriCure has higher upside potential than Retractable Technologies, analysts believe AtriCure is more attractive than Retractable Technologies.

AtriCure has a beta of 1.535, which suggesting that the stock is 53.473% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.083, suggesting its more volatile than the S&P 500 by 108.265%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

AtriCure quarterly revenues are $124.3M, which are larger than Retractable Technologies quarterly revenues of $10.3M. AtriCure's net income of -$15.6M is lower than Retractable Technologies's net income of -$1.9M. Notably, AtriCure's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 0.55x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -12.53% compared to AtriCure's net margin of -1226.82%. AtriCure's return on equity of -9.67% beat VolitionRX's return on equity of --.

AtriCure has a consensus price target of $52.22, signalling upside risk potential of 64.07%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 555.14%. Given that VolitionRX has higher upside potential than AtriCure, analysts believe VolitionRX is more attractive than AtriCure.

AtriCure has a beta of 1.535, which suggesting that the stock is 53.473% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $124.3M, which are larger than VolitionRX quarterly revenues of $474.5K. AtriCure's net income of -$15.6M is lower than VolitionRX's net income of -$5.8M. Notably, AtriCure's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 33.23x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -12.53% compared to AtriCure's net margin of -4291.67%. AtriCure's return on equity of -9.67% beat Catheter Precision's return on equity of -65.84%.

AtriCure has a consensus price target of $52.22, signalling upside risk potential of 64.07%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 436.19%. Given that Catheter Precision has higher upside potential than AtriCure, analysts believe Catheter Precision is more attractive than AtriCure.

AtriCure has a beta of 1.535, which suggesting that the stock is 53.473% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $124.3M, which are larger than Catheter Precision quarterly revenues of $96K. AtriCure's net income of -$15.6M is lower than Catheter Precision's net income of -$4.1M. Notably, AtriCure's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 0.99x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -12.53% compared to AtriCure's net margin of -10.04%. AtriCure's return on equity of -9.67% beat Xtant Medical Holdings's return on equity of -35.34%.

AtriCure has a consensus price target of $52.22, signalling upside risk potential of 64.07%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 265.35%. Given that Xtant Medical Holdings has higher upside potential than AtriCure, analysts believe Xtant Medical Holdings is more attractive than AtriCure.

AtriCure has a beta of 1.535, which suggesting that the stock is 53.473% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $124.3M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. AtriCure's net income of -$15.6M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, AtriCure's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.